Table 5D.
Strong RBD-IgG antibody decline for kidney transplant recipients (n = 104).
| Risk factor | OR | 95% CI | p-value |
|---|---|---|---|
| Age | 1·017 | [0·973,1·064] | 0·458 |
| Sex (Ref. = female) | 1·559 | [0·550,4·419] | 0·403 |
| Time after transplantation | 0·987 | [0·920,1·058] | 0·703 |
| Vaccine type (Ref. = mRNA-1273) | 1·492 | [0·522,4·262] | 0·455 |
| IS number | 1·064 | [0·499,2·267] | 0·872 |
| BMI | 1·096 | [0·987,1·267] | 0·086 |
| Hep B vacc failure | 4·037 | [0·903,18·042] | 0·068 |
| Diabetes mellitus | 0·717 | [0·231,2·658] | 0·854 |
Ref. = reference category; a “strong RBD-IgG antibody decline” between T2 (two months after first vaccination) and T3 (six months) was defined as described in Results and in more detail in Supplementary material. Comparator is the MP cohort. IS means immunosuppressive drug; BMI means body mass index; Hep B vacc failure definition - patients with unsuccessful vaccination after at least four attempts.
Model fit: AIC = 127.16; BIC = 127.16